Metastatic lung cancer patients miss life-extending treatment, study finds
Updated
Updated · The New York Times · May 7
Metastatic lung cancer patients miss life-extending treatment, study finds
7 articles · Updated · The New York Times · May 7
The JAMA Oncology study examined more than 250,000 Medicare patients from 2006 to 2021, average age 73, and found treatment rates rose only from 45% to 48%.
Researchers said they could not pinpoint causes, but experts cited delayed diagnosis, poor screening uptake, follow-up bottlenecks, access problems, fatalism and shame as likely barriers.
Lung cancer remains the deadliest US cancer, with more than 110,000 metastatic diagnoses annually, despite newer chemotherapy, immunotherapy and targeted drugs that can extend survival for some patients.
With revolutionary cancer drugs now available, why are more than half of U.S. patients still not receiving them?
Could AI solve the deadly delays in diagnosing and treating America's top cancer killer?
Closing the 52% Treatment Gap in Metastatic Lung Cancer Among Medicare Beneficiaries
Overview
A landmark 2026 study reveals that over half of Medicare patients with metastatic lung cancer received no life-extending treatment from 2006 to 2021, despite medical advances. This treatment gap, driven by geographic, socioeconomic, healthcare system, psychosocial, and provider challenges, contributes to high mortality, with 40% dying within 90 days of diagnosis. Early diagnosis remains low, worsening survival disparities, especially among Black and Hispanic patients who face lower treatment rates due to systemic barriers and economic instability. These gaps in care access largely explain racial survival differences, highlighting the urgent need for coordinated efforts to improve early detection, equitable treatment access, and reduce disparities nationwide.